A 58-year-old man with type 2 diabetes mellitus on metformin monotherapy presents with persistent hyperglycemia (FBS 180 mg/dL, PPBS 240 mg/dL). Regarding the addition of a second agent, all of the following statements about DPP-4 inhibitors are true EXCEPT:

Explanation

## DPP-4 Inhibitors: Profile and Adverse Effects **Key Point:** DPP-4 inhibitors (sitagliptin, vildagliptin, linagliptin) are incretin enhancers that are **weight-neutral** and **do NOT cause hypoglycemia** when used as monotherapy or in combination with metformin. ### Mechanism of Action ```mermaid flowchart LR A[Meal intake]:::action --> B[GLP-1 secretion]:::outcome B --> C[DPP-4 normally<br/>degrades GLP-1]:::outcome C --> D[Short GLP-1 half-life<br/>5-7 minutes]:::outcome E[DPP-4 Inhibitor]:::action --> F[Blocks DPP-4]:::action F --> G[Increased GLP-1<br/>concentration]:::outcome G --> H[Enhanced insulin<br/>secretion]:::action G --> I[Delayed gastric<br/>emptying]:::action H --> J[Improved glycemic<br/>control]:::outcome ``` ### Safety Profile Comparison | Feature | DPP-4 Inhibitors | Sulfonylureas | GLP-1 Agonists | |---------|------------------|---------------|----------------| | **Hypoglycemia risk** | Minimal (glucose-dependent) | High | Low | | **Weight change** | Neutral | Weight gain | Weight loss | | **GI side effects** | Rare | None | Common (nausea) | | **Pancreatitis risk** | Rare but reported | None | Reported | | **Cardiac safety** | Neutral/protective | Neutral | Cardioprotective | ### Why Option 1 is INCORRECT **High-Yield:** DPP-4 inhibitors do **NOT** cause weight gain or hypoglycemia when used as monotherapy or with metformin because: 1. **Glucose-dependent mechanism** — They enhance insulin secretion only when blood glucose is elevated; no insulin release in fasting state 2. **Weight-neutral** — No metabolic effects that promote weight gain 3. **No hypoglycemia risk** — Unlike sulfonylureas, they do not stimulate insulin release when glucose is low **Clinical Pearl:** This makes DPP-4 inhibitors ideal for elderly patients or those at high risk of hypoglycemia. ### Correct Statements Explained **Option 0 (Correct):** GLP-1 is normally degraded by DPP-4 within 5–7 minutes; inhibiting DPP-4 extends GLP-1 half-life to ~30 minutes, amplifying its glucose-lowering effect. **Option 2 (Correct):** DPP-4 inhibitors improve both fasting (via enhanced basal insulin) and postprandial glucose (via meal-stimulated GLP-1 action). **Option 3 (Correct):** DPP-4 inhibitors have demonstrated cardioprotective effects (e.g., sitagliptin in TECOS trial) and are safe in heart failure; some agents (saxagliptin) require caution in HF with reduced ejection fraction. **Warning:** Rare but serious adverse effects include acute pancreatitis and Stevens-Johnson syndrome; monitor for abdominal pain and skin rashes. [cite:KD Tripathi 8e Ch 27]